EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib ( TAK ‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis

Amit Choudhury iD, Jie Cheng, Jay Tang, Sachin Kumar, Banishree Saha iD, Vinayagam Arunachalam, Ting Hong, Ejim Mark, Håkan Wennbo, Iain B McInnes iD

ACR Open Rheumatology · 2026-09 · 8 (9)

DOI: 10.1002/acr2.90124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 14.09.2026. Verfasst von Amit Choudhury und 9 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc, Cambridge, Massachusetts. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Development Center Americas, Inc.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This post hoc analysis evaluated the effect of zasocitinib, an investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 (TYK2) inhibitor in late‐stage clinical development, on TYK2 signaling response and disease‐related biomarkers and the association of these changes with clinical response in patients with active psoriatic arthritis from a phase 2b trial (NCT05153148).

Methods

Blood samples were collected predose from patients receiving zasocitinib 15 mg, 30 mg, or placebo once daily on Day 1 (baseline), Week 4, and Week 12. Plasma biomarkers related to TYK2 signaling response, inflammation, skin and joint pathogenesis, cartilage/bone turnover, and bone formation were measured using Olink Explore HT, Olink Target 48, or Nordic BioScience platforms.

Results

As early as Week 4 and through Week 12, in patients receiving zasocitinib 15 or 30 mg, reductions in analyzed biomarkers were observed. Among American College of Rheumatology 20% improvement criteria (ACR20) and Psoriasis Area and Severity Index 75% improvement criteria (PASI 75) responders, reductions in TYK2‐ and skin‐joint‐related biomarkers occurred following zasocitinib treatment from baseline to Week 12. Maintenance of baseline bone formation biomarkers was observed in ACR20 responders receiving zasocitinib. Patients with high baseline levels (≥ median) of TYK2‐ and skin‐joint‐related biomarkers receiving zasocitinib achieved greater ACR20 and PASI 75 response rates than those receiving placebo.

Conclusion

Reductions in biomarkers related to TYK2 signaling response, inflammation, skin and joint pathogenesis, and cartilage/bone turnover, along with maintenance of bone formation biomarkers at Week 4, occurred following zasocitinib treatment; associations with clinical response (ACR20 and PASI 75) were observed. image

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
  • College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

ORCID-Profile: Amit Choudhury, Banishree Saha, Iain B McInnes

Förderung

  • Takeda Development Center Americas, Inc

Zitieren

APA

Choudhury, A., Cheng, J., Tang, J., Kumar, S., Saha, B., Arunachalam, V., Hong, T., Mark, E., Wennbo, H., & McInnes, I. B. (2026). Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib ( TAK ‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis. ACR Open Rheumatology, 8(9). https://doi.org/10.1002/acr2.90124

Vancouver

Choudhury A, Cheng J, Tang J, Kumar S, Saha B, Arunachalam V, et al. Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib ( TAK ‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis. ACR Open Rheumatology. 2026;8(9). doi:10.1002/acr2.90124

BibTeX
@article{Choudhury2026,
  author = {Choudhury, Amit and Cheng, Jie and Tang, Jay and Kumar, Sachin and Saha, Banishree and Arunachalam, Vinayagam and Hong, Ting and Mark, Ejim and Wennbo, Håkan and McInnes, Iain B},
  title = {Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib ( TAK ‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {9},
  doi = {10.1002/acr2.90124}
}
Kostenlos starten →